{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-083629","form_type":"8-K","ticker":"KNSA","cik":"0001730430","company_name":"Kiniksa Pharmaceuticals International, plc","filed_at":"2023-07-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.025743+00:00","generated_at":"2026-06-13T03:14:33.808328+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Kiniksa Q2 ARCALYST revenue $54.5M; raises FY2023 guidance to $220-230M","bullets":["Q2 total revenue $71.5M (vs $27.0M YoY), ARCALYST net product revenue $54.5M (vs $27.0M YoY).","Net income $15.0M vs net loss $20.0M YoY; includes $16.2M tax benefit from valuation allowance release.","2023 ARCALYST revenue guidance raised to $220-230M from $200-215M; cash runway extended into at least 2027.","Over 1,250 prescribers have written ARCALYST; average therapy duration ~20 months; 45% of patients restarted within 8 weeks.","KPL-404 Phase 2 rheumatoid arthritis data expected in 1H 2024; $15.0M milestone from Genentech vixarelimab agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-083629","json":"https://secwatch.observer/filing/0001104659-23-083629.json","markdown":"https://secwatch.observer/filing/0001104659-23-083629.md","text":"https://secwatch.observer/filing/0001104659-23-083629.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730430/000110465923083629/0001104659-23-083629-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730430/000110465923083629/tm2321659d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T03:14:33.808328+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a51009e67abf32e676c6825da8ef67d94a0d7334","claim":"Kiniksa Pharmaceuticals International, plc reported quarter ended June 30, 2023 results: revenue $71.5 million, net income $15.0 million. Guidance raised.","evidence_excerpt":"Financial Results • Total revenue for the second quarter of 2023 was $71.5 million, compared to $27.0 million for the second quarter of 2022. - Total revenue for the second quarter of 2023 included $54.5 million in ARCALYST net product revenue and $17.0 million in license and collaboration revenue, compared to $27.0 million in ARCALYST net product revenue and $0.0 million in license and collaboration revenue for the second quarter of 2022. • Total operating expenses for the second quarter of 2023 were $74.6 million, compared to $46.3 million for the second quarter of 2022. - Total operating expenses for the second quarter of 2023 included $6.5 million in non-cash, share-based compensation expense, compared to $6.7 million for the second quarter of 2022. • Net income for the second quarter of 2023 was $15.0 million, compared to a net loss of $20.0 million for the second quarter of 2022. - Net income for the second quarter of 2023 included a $16.2 million tax benefit primarily due to the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1730430/000110465923083629/0001104659-23-083629-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended June 30, 2023"},{"label":"Revenue","value":"$71.5 million"},{"label":"Net income","value":"$15.0 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}